ABSTRACT
Background The CCL2/CCR2 axis governs monocyte trafficking and recruitment to atherosclerotic lesions. Human genetic analyses and population-based studies support an association between circulating CCL2 levels and atherosclerosis. Still, it remains unknown whether pharmacological targeting of CCR2, the main CCL2 receptor, would provide protection against human atherosclerotic disease.
Methods In whole-exome sequencing data from 454,775 UK Biobank participants (40-69 years), we identified predicted loss-of-function (LoF) or damaging missense (REVEL score >0.5) variants within the CCR2 gene. We prioritized variants associated with lower monocyte count (p<0.05) and tested associations with vascular risk factors and risk of atherosclerotic disease over a mean follow-up of 14 years. The results were replicated in a pooled cohort of three independent datasets (TOPMed, deCODE and Penn Medicine BioBank; total n=441,445) and the effect of the most frequent damaging variant was experimentally validated.
Results A total of 45 predicted LoF or damaging missense variants were identified in the CCR2 gene, 4 of which were also significantly associated with lower monocyte count, but not with other white blood cell counts. Heterozygous carriers of these variants were at a lower risk of a combined atherosclerosis outcome, showed a lower burden of atherosclerosis across four vascular beds, and were at a lower lifetime risk of coronary artery disease and myocardial infarction. There was no evidence of association with vascular risk factors including LDL-cholesterol, blood pressure, glycemic status, or C-reactive protein. Using a cAMP assay, we found that cells transfected with the most frequent CCR2 damaging variant (3:46358273:T:A, M249K, 547 carriers, frequency: 0.14%) show a decrease in signaling in response to CCL2. The associations of the M249K variant with myocardial infarction were consistent across cohorts (ORUKB: 0.62 95%CI: 0.39-0.96; ORexternal: 0.64 95%CI: 0.34-1.19; ORpooled: 0.64 95%CI: 0.45-0.90). In a phenome-wide association study, we found no evidence for higher risk of common infections or mortality among carriers of damaging CCR2 variants.
Conclusions Heterozygous carriers of damaging CCR2 variants have a lower burden of atherosclerosis and lower lifetime risk of myocardial infarction. In conjunction with previous evidence from experimental and epidemiological studies, our findings highlight the translational potential of CCR2-targeting as an atheroprotective approach.
Competing Interest Statement
SMD receives research support from RenalytixAI and personal fees from Calico Labs, both outside the current work. MEM receives funding from Regeneron Pharmaceutical Inc. unrelated to this work. RD has received research support from AstraZeneca and Goldfinch Bio, not related to this work. BMP serves on the Steering Committee of the Yale Open Data Access Program funded by Johnson & Johnson. LMR is a consultant for the TOPMed Administrative Coordinating Center (through WeStat). The other authors have nothing to declare.
Funding Statement
Marios K. Georgakis is supported with a Walter-Benjamin fellowship (GZ: GE 3461/1-1, ID: 466957018), a clinician-scientist grant from the Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198), and an Emmy Noether grant (GZ: GE 3461/2-1, ID 512461526) by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), as well as by the Fritz-Thyssen Foundation (Ref. 10.22.2.024MN) and the Hertie Foundation (Hertie Network of Excellence in Clinical Neuroscience, ID P1230035). Scott M. Damrauer is supported by IK2-CX001780. We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient-participants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. Paul S. de Vries, Natalie R. Hasbani, and Alanna C. Morrison were supported by R01 HL146860. Joshua C. Bis and Bruce M. Psaty were funded in part by R01HL105756. Reading of the carotid IMT measures was supported by N01HC85085, N01HC45133; Coronary Calcium scans were supported by R01HL64587. Kendra A. Young is supported by NHLBIn U01 HL089897 and U01 HL089856. Sharon M. Lutz was supported by R01 MH129337. Nicholette D. Palmer, Barry I. Freedman and Donald W. Bowden were supported by R01 AG058921. Patricia A. Peyser was supported by R01 HL146860. Lawence F. Bielak was supported by R01 HL146860. LMR was supported by T32 HL129982 and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR002490. Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Cohort-specific acknowledgements for studies included in the TOPMed program are provided in Supplementary Table S7. Martin Dichgans is supported by grants from the Deutsche Forschungsgemeinschaft (DFG; CRC 1123 [B3], DI-722/16-1 [ID: 428668490], DI-722/21-1, and Munich Cluster for Systems Neurology [SyNergy, EXC 2145; ID390857198]), the Leducq Foundation, and the Vascular Dementia Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies have received ethical approvals from the respective ethical authorities and participants in all studies have provided written informed consent. The UKB has institutional review board approval from the Northwest Multi‐Center Research Ethics Committee (Manchester, UK). We accessed the data following approval of an application by the UKB Ethics and Governance Council (Application No. 36993 and 2532). Summary results from deCODE, TOPMed, and PMBB were obtained following a common pre-defined research protocol to principal investigators of the study and are presented in the figures and supplementary tables. deCODE has been approved by the National Bioethics Committee of Iceland, and the study was conducted in agreement with conditions issued by the Data Protection Authority of Iceland (VSN_14-015). All common research protocols for the TOPMed Program have been approved by the institutional review board at the University of Maryland Baltimore, whereas individual participating studies have obtained ethical approval from their local ethical authorities, as described previously.45 The Penn Medicine BioBank is approved by the University of Pennsylvania.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from the UKB are available upon submission and approval of a research proposal.
